The glycocalyx sugar structure on the blood vessel lining sheds into the bloodstream in disease-specfic patterns. This biology has won a Nobel Prize. Our Technology Measures It.
Unlocking novel biomarkers to transform patient outcomes
Clinical-stage blood test platform for diagnosing and monitoring brain diseases.
The Biology
A quick guided intro to what is is, how it works, who’s behind it and what the benefits are.
Healthy
Sick
Accurate, Low-Cost, Scalable
Our patented technology measures glycocalyx fragments in blood, and through machine learning, unlocks the disease-specific GLX Signature.
-
1
Blood test
It starts with a simple blood test
It starts with a simple blood test
-
2
Bio analysis
Glycocalyx is measured and bio-analyzed with AI/ML
Glycocalyx is measured and bio-analyzed with AI/ML
-
3
Report
Actionable, precision medicine GLX Signature report
Actionable, precision medicine GLX Signature report
-
4
Better Patient Outcomes
At GLX Analytix, we are putting patients at the center of everything we do. We believe that our diagnosis and monitoring lead to better patient outcomes.
Diagnosis, Monitoring, and Treatment Decisions
Personalized Medicine for neuropsychiatric, neurodegenerative and autoimmune diseases
Our Science
-
Reading the vascular fingerprint after stroke
By tracking glycocalyx fragments in patients after stroke, this study reveals a complex, multi-dimensional blood signature that evolves with recovery — suggesting the GLX signature could serve as a composite biomarker for cerebrovascular health.
View in Journal -
A blood test for psychosis
The GLX Signature platform detects schizophrenia from a blood sample and correlates with severity of psychosis
View in Journal -
The GLX Signature in Parkinson's Disease
Parkinson's disease has a distinct glycocalyx signature in blood, with potential to predict progression.
View in Journal -
A new class of biomarkers for Multiple Sclerosis
This study presents the first evidence that glycocalyx shedding in blood can be detected before clinical symptoms appear in experimental models of MS, opening the door to earlier diagnosis and monitoring.
Read Article -
Seeing the glycocalyx in a living brain
Using advanced two-photon microscopy, researchers mapped the brain's endothelial glycocalyx in vivo with nanoscale precision — revealing its spatial organization, transport dynamics, and molecular interactions across the vascular tree of the living brain.
Read Article
About
Leadership
-
Scientific Advisor
Assay Development and Commercialization Andreas Jeromin, MD, PhD
Scientific Advisor Assay Development and Commercialization Andreas Jeromin, MD, PhDAndreas is a leading expert in CNS biomarker discovery and commercialization, specializing in neurology and neurodegeneration. Over 25+ years, he has successfully developed multiple diagnostic CNS biomarkers and advanced key biomarker platforms. As former CSO of ALZPath and Cohen Veterans Biosciences and Scientific Advisor at Quanterix, he pioneered high-precision biomarker detection and with over 200 publications, he is a key-opinion leader (KOL) in translational strategies, assay standardization and commercialization.
-
Chief Commercial Officer Maital Rasmussen
Chief Commercial Officer Maital RasmussenMaital is a global leader in health technology commercialization, with over 20 years of experience scaling businesses across Fortune 100 companies and startups. As former Chief Commercial Officer at Octave Bioscience, she successfully launched neuroscience precision medicine portfolios and drove revenue growth across providers, payers, and pharma. Maital has held leadership roles, including Global Head of Marketing at Roche, Marketing Director at Oracle Health Sciences, and Vice President at JPMorgan. She currently serves as a Board Member at Pluri (NASDAQ: PLURPSTI).
-
CMO & CRO
Chief Medical and Regulatory Officer Richard Frank, MD, PhD
CMO & CRO Chief Medical and Regulatory Officer Richard Frank, MD, PhDFormer Chief Medical Officer of Siemens Healthineers with four decades of experience in clinical trials, regulatory labeling, reimbursement, and clinical adoption of therapeutic and diagnostic products, Dr. Frank has provided expert testimony to Congress, engaged with peers in professional societies and patient advocacy groups, served on FDA Advisory Committees, and contributed to key industry efforts with MEDCAC, CMS, the World Bank, WHO, National Academy of Sciences et al. A pioneer in AI/ML for medical imaging, Dr. Frank chaired the AMA’s AI Working Group for AI Taxonomy, and has been a member of the CPT Editorial Panel since 2022, now chairing their Digital Medicine Coding Committee.
-
Brian is a neuroscientist-turned-entrepreneur who completed his PhD together with Novo Nordisk, where his groundbreaking research on an earlier version of Ozempic led to first-in-field discoveries and multiple patents. After uncovering novel insights into the blood-brain barrier, he founded GLX Analytix to revolutionize brain health through blood-based biomarkers. Under Brian's leadership, GLX Analytix has developed the GLX Signature Platform, combining advanced vascular biology with AI to transform precision medicine for conditions ranging from ALS to Clinical Depression. The company has secured backing from leading healthcare investors including LabCorp, ADDF, and Digital Dx Ventures, while generating early revenue through pharmaceutical partnerships. Recipient of the Roche Future x Healthcare Startup Award and nominated for the Prix Galien USA, GLX Analytix is an inaugural industry member at the Harvard/Wyss Institute Diagnostic Accelerator, and is powered by collaborations with clinicians across North America from Mass General Hospital in Boston to Cedars Sinai in the Pacific to address high unmet medical needs.
-
Chief Financial Officer Nancy Hargreaves
Chief Financial Officer Nancy HargreavesNancy brings over 20 years of experience in financial strategy, fundraising, and operational excellence, having led major funding initiatives for several clients who have collectively raised over $300m in the last few years, with a focus on guiding early-stage commercialization and high-growth companies in the MedTech and life sciences sectors.
-
Chair of the Board Michele Colucci
Chair of the Board Michele ColucciMichele is the Chair of GLX Analytix and the Founder and CEO of Digital Dx Ventures, a Silicon Valley venture fund investing in the future of healthcare and the West Coast ambassador to the Nobel Laureate Foundation.
News
-
Roche Award
GLX has been awarded the Roche Startup Award 2019 at the Future Healthcare event in Munich, recognizing their innovative approach of combining proprietary biomarkers with machine learning for earlier detection and more effective treatment of autoimmune and neurodegenerative diseases.
Read press release -
Strategic Growth Investment
GLX Analytix announces a strategic investment from Labcorp Venture Fund and the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator, as part of an oversubscribed round led by DigitalDx Ventures, to accelerate development of its platform for early detection of neurodegenerative and autoimmune diseases.
Read press release -
Harvard Wyss Diagnostic Accelerator
GLX Analytix joins Harvard's Wyss Diagnostics Accelerator as an Industrial Participant, connecting with clinicians, researchers, and funding institutions to accelerate transformative diagnostic technologies — furthering the mission to bring personalized medicine for neurodegenerative and autoimmune diseases to patients worldwide.
Read press release -
Galien Prize
GLX Analytix is officially recognized as a 2023 Prix Galien USA nominee in the Best Startup category by a distinguished awards committee featuring global life sciences leaders from Roche, Pfizer, Johnson & Johnson, AstraZeneca, and more.
Read press release -
Expansion of GLX Team
GLX Analytix strengthens its leadership with Michele Colucci as new Chair of the Board, expanded C-suite additions, and new Advisory Board members spanning venture capital, health tech, regulatory strategy, and neurodegenerative disease expertise — reinforcing the company's path to commercialization.
Read press release -
Expansion of GLX SAB
GLX Analytix appoints Don Hardison, former CEO of Exact Sciences, and neuroradiologist Jeremy Nathan Ford, MD from Massachusetts General Hospital to its Scientific Board of Directors, advancing precision medicine in neurology and accelerating market adoption of its blood-based neuroscience diagnostics platform.
Read press release